CN101028384A - 一种用于治疗妇科炎症的药物组合物及其制备方法和质量控制方法 - Google Patents
一种用于治疗妇科炎症的药物组合物及其制备方法和质量控制方法 Download PDFInfo
- Publication number
- CN101028384A CN101028384A CNA2007100959973A CN200710095997A CN101028384A CN 101028384 A CN101028384 A CN 101028384A CN A2007100959973 A CNA2007100959973 A CN A2007100959973A CN 200710095997 A CN200710095997 A CN 200710095997A CN 101028384 A CN101028384 A CN 101028384A
- Authority
- CN
- China
- Prior art keywords
- solution
- add
- weight portions
- phoenix
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 35
- 239000000203 mixture Substances 0.000 title claims description 24
- 238000004519 manufacturing process Methods 0.000 title description 3
- 239000003814 drug Substances 0.000 claims abstract description 123
- 208000003251 Pruritus Diseases 0.000 claims abstract description 13
- 239000000463 material Substances 0.000 claims abstract description 11
- 238000003908 quality control method Methods 0.000 claims abstract description 7
- 208000004926 Bacterial Vaginosis Diseases 0.000 claims abstract description 6
- 230000008569 process Effects 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims description 81
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 77
- 238000012360 testing method Methods 0.000 claims description 75
- 239000000243 solution Substances 0.000 claims description 65
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 57
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 56
- 239000007788 liquid Substances 0.000 claims description 40
- 241000628997 Flos Species 0.000 claims description 36
- 239000000341 volatile oil Substances 0.000 claims description 36
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 34
- 239000000706 filtrate Substances 0.000 claims description 31
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 28
- 239000000047 product Substances 0.000 claims description 28
- 238000002360 preparation method Methods 0.000 claims description 25
- 239000000284 extract Substances 0.000 claims description 24
- 239000013558 reference substance Substances 0.000 claims description 24
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 19
- 239000003208 petroleum Substances 0.000 claims description 19
- 239000000829 suppository Substances 0.000 claims description 16
- 241000237636 Pheretima Species 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 241001438943 Callicarpa kwangtungensis Species 0.000 claims description 13
- 239000003921 oil Substances 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 11
- 238000005406 washing Methods 0.000 claims description 11
- 206010047799 Vulvovaginitis trichomonal Diseases 0.000 claims description 10
- 230000033228 biological regulation Effects 0.000 claims description 10
- 230000006837 decompression Effects 0.000 claims description 10
- 238000002474 experimental method Methods 0.000 claims description 10
- 239000000741 silica gel Substances 0.000 claims description 10
- 229910002027 silica gel Inorganic materials 0.000 claims description 10
- 235000019640 taste Nutrition 0.000 claims description 10
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 claims description 9
- -1 filter Substances 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 239000007921 spray Substances 0.000 claims description 9
- 238000004809 thin layer chromatography Methods 0.000 claims description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 8
- 230000002879 macerating effect Effects 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 7
- 239000012567 medical material Substances 0.000 claims description 7
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 claims description 6
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 239000000890 drug combination Substances 0.000 claims description 6
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 claims description 6
- 125000005456 glyceride group Chemical group 0.000 claims description 6
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 claims description 6
- 229930014456 matrine Natural products 0.000 claims description 6
- 238000001556 precipitation Methods 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 238000003556 assay Methods 0.000 claims description 5
- 238000009835 boiling Methods 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 239000002244 precipitate Substances 0.000 claims description 5
- 238000004064 recycling Methods 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 claims description 3
- 239000005770 Eugenol Substances 0.000 claims description 3
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 claims description 3
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 claims description 3
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 claims description 3
- 229940093265 berberine Drugs 0.000 claims description 3
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 claims description 3
- ONBIUAZBGHXJDM-UHFFFAOYSA-J bismuth;potassium;tetraiodide Chemical compound [K+].[I-].[I-].[I-].[I-].[Bi+3] ONBIUAZBGHXJDM-UHFFFAOYSA-J 0.000 claims description 3
- 229960002217 eugenol Drugs 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 claims description 3
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 238000011003 system suitability test Methods 0.000 claims description 3
- 239000012085 test solution Substances 0.000 claims description 3
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 claims description 3
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 claims description 3
- 235000012141 vanillin Nutrition 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 2
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 claims description 2
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 2
- 238000005374 membrane filtration Methods 0.000 claims description 2
- XYKIUTSFQGXHOW-UHFFFAOYSA-N propan-2-one;toluene Chemical compound CC(C)=O.CC1=CC=CC=C1 XYKIUTSFQGXHOW-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000007803 itching Effects 0.000 abstract description 9
- 241000361919 Metaphire sieboldi Species 0.000 abstract description 2
- 244000223014 Syzygium aromaticum Species 0.000 abstract description 2
- 235000016639 Syzygium aromaticum Nutrition 0.000 abstract description 2
- 235000013399 edible fruits Nutrition 0.000 abstract description 2
- 241000219784 Sophora Species 0.000 abstract 1
- 208000007074 Trichomonas Vaginitis Diseases 0.000 abstract 1
- 208000025206 Trichomonas vaginitis urogenital infection Diseases 0.000 abstract 1
- 241000233805 Phoenix Species 0.000 description 105
- 241001465754 Metazoa Species 0.000 description 38
- 229960004756 ethanol Drugs 0.000 description 21
- 239000011159 matrix material Substances 0.000 description 18
- 239000000843 powder Substances 0.000 description 17
- 210000001215 vagina Anatomy 0.000 description 17
- 230000001580 bacterial effect Effects 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 239000008921 jie er yin Substances 0.000 description 14
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical group C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 description 11
- 230000000844 anti-bacterial effect Effects 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 230000008961 swelling Effects 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 239000011248 coating agent Substances 0.000 description 9
- 238000000576 coating method Methods 0.000 description 9
- 238000001035 drying Methods 0.000 description 9
- 239000008187 granular material Substances 0.000 description 9
- 239000002674 ointment Substances 0.000 description 9
- 235000014347 soups Nutrition 0.000 description 9
- 241000191963 Staphylococcus epidermidis Species 0.000 description 8
- 206010046914 Vaginal infection Diseases 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 235000013372 meat Nutrition 0.000 description 8
- 210000003371 toe Anatomy 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 206010070834 Sensitisation Diseases 0.000 description 6
- 235000010418 carrageenan Nutrition 0.000 description 6
- 229920001525 carrageenan Polymers 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000000386 microscopy Methods 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 230000008313 sensitization Effects 0.000 description 6
- 241000700199 Cavia porcellus Species 0.000 description 5
- 229920000858 Cyclodextrin Polymers 0.000 description 5
- 239000001116 FEMA 4028 Substances 0.000 description 5
- 241000588653 Neisseria Species 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 5
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 5
- 229960004853 betadex Drugs 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 229960001660 histamine phosphate Drugs 0.000 description 5
- ZHIBQGJKHVBLJJ-UHFFFAOYSA-N histamine phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.NCCC1=CNC=N1 ZHIBQGJKHVBLJJ-UHFFFAOYSA-N 0.000 description 5
- 108010084652 homeobox protein PITX1 Proteins 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical group CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 240000006409 Acacia auriculiformis Species 0.000 description 4
- 241000194032 Enterococcus faecalis Species 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 241000235070 Saccharomyces Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000012531 culture fluid Substances 0.000 description 4
- 230000035617 depilation Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 210000005069 ears Anatomy 0.000 description 4
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 4
- 229960000785 fluocinonide Drugs 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical group [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 241000588767 Proteus vulgaris Species 0.000 description 3
- 241000224527 Trichomonas vaginalis Species 0.000 description 3
- 201000008100 Vaginitis Diseases 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000679 carrageenan Substances 0.000 description 3
- 229940113118 carrageenan Drugs 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000009849 deactivation Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000007938 effervescent tablet Substances 0.000 description 3
- 229960001347 fluocinolone acetonide Drugs 0.000 description 3
- 239000004570 mortar (masonry) Substances 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 229940007042 proteus vulgaris Drugs 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 238000011121 vaginal smear Methods 0.000 description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 208000036649 Dysbacteriosis Diseases 0.000 description 2
- 208000027244 Dysbiosis Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241001360526 Escherichia coli ATCC 25922 Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 235000009392 Vitis Nutrition 0.000 description 2
- 241000219095 Vitis Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 210000003756 cervix mucus Anatomy 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000007140 dysbiosis Effects 0.000 description 2
- 239000008157 edible vegetable oil Substances 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000749 insecticidal effect Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 206010046901 vaginal discharge Diseases 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241001614060 Amynthas aspergillus Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 206010003693 Atrophic vulvovaginitis Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000131317 Capitulum Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- 235000018959 Chrysanthemum indicum Nutrition 0.000 description 1
- 240000005250 Chrysanthemum indicum Species 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 241000125183 Crithmum maritimum Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 244000061408 Eugenia caryophyllata Species 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000243684 Lumbricus Species 0.000 description 1
- 206010062049 Lymphocytic infiltration Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000219926 Myrtaceae Species 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 244000137852 Petrea volubilis Species 0.000 description 1
- 241000972673 Phellodendron amurense Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 235000019084 Selinum monnieri Nutrition 0.000 description 1
- 244000296102 Selinum monnieri Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 241000246044 Sophora flavescens Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- 208000037009 Vaginitis bacterial Diseases 0.000 description 1
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010048245 Yellow skin Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 102000011759 adducin Human genes 0.000 description 1
- 108010076723 adducin Proteins 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 239000006053 animal diet Substances 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000000941 anti-staphylcoccal effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 241000933856 bacterium 8 Species 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000002389 essential drug Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000010820 immunofluorescence microscopy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 201000005630 leukorrhea Diseases 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 238000012009 microbiological test Methods 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 201000010808 postmenopausal atrophic vaginitis Diseases 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 238000010181 skin prick test Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Abstract
Description
药物 | 动物数(只) | 药物浓度(%) | 阴道分泌物涂片镜检虫体数(x±s) | 抑虫率(%) |
空白对照组模型组甲硝唑组凤花洁阴栓组凤花洁阴栓组凤花洁阴栓组凤花洁阴栓组 | 6666666 | --30102550100 | 095.0±2.5018.0±4.26.0±3.100 | --10078.693.3100100 |
菌株 | MIC(g/ml) | MBC(g/ml) |
大肠杆菌ATCC25922株金黄色葡萄球菌ATCC25925株绿脓杆菌ATCC27853株表皮葡萄球菌ATCC26069株变形杆菌49010株粪链球菌32221株淋病奈瑟氏菌29106株白色假丝酵母菌85021株 | 0.1250.1250.250.06250.250.1250.0310.125 | 0.250.250.50.1250.250.50.1250.25 |
菌株 | 株数 | MIC范围 | MIC50 | MIC90 | MBC范围 |
金黄葡菌大肠杆菌表皮葡菌变形杆菌淋球菌加特纳菌白念珠菌 | 100100809024850 | 0.0625~0.250.125~0.50.125~0.50.125~0.50.0156~0.06250.125~0.250.0625~0.25 | 0.12250.23250.21950.25420.03390.15630.1050 | 0.17930.28470.28420.30620.04030.19320.1324 | 0.125~0.50.25~0.50.25~0.50.25~0.50.03125~0.1250.250.125~0.5 |
菌株 | MIC(生药g/ml) | ||
pH 5.7 | pH 7.2 | pH 8.5 | |
金黄色葡萄球ATCC25925株表皮葡萄球菌ATCC26069株 | 0.1250.0625 | 0.1250.0625 | 0.1250.0625 |
菌株 | MIC(生药g/ml) | ||
104 | 106 | 108 | |
金黄色葡萄球ATCC25925株表皮葡萄球菌ATCC26069株 | 0.1250.0625 | 0.1250.0625 | 0.1250.0625 |
组别 | 动物数(只) | 剂量 | 痒反应次数(x±s) |
空白组洁尔阴组肤轻松组凤花洁阴栓大剂量组凤花洁阴栓中剂量组凤花洁阴栓小剂量组 | 101010101010 | -0.05ml0.05g100%50%25% | 20.4±7.817.3±7.913.0±6.4*13.8±4.6*15.1±6.719.5±10.2 |
组别 | 动物数(只) | 剂量 | 肿胀度(g,x±s) |
空白组洁尔阴组肤轻松组凤花洁阴栓大剂量组凤花洁阴栓中剂量组凤花洁阴栓小剂量组 | 211821222221 | -0.05ml0.05g100%50%25% | 0.0070±0.00350.0071±0.00390.0044±0.0045*0.0026±0.0023**0.0069±0.00350.0060±0.0026 |
组别 | 动物数 | 不同时间的足趾肿胀度(ml) | ||||
0.5小时 | 1.0小时 | 2.0小时 | 4.0小时 | 6.0小时 | ||
空白组洁尔阴组肤轻松组凤花洁阴栓凤花洁阴栓凤花洁阴栓 | 101010111110 | 0.277±0.0460.259±0.1030.235±0.1710.194±0.079**0.229±0.0990.320±0.173 | 0.527±0.2460.435±0.2010.414±0.241*0.548±0.1660.469±0.2670.427±0.180 | 0.561±0.2100.412±0.1920.310±0.192*0.531±0.1850.604±0.3080.570±0.257 | 0.615±0.1100.465±0.2340.282±0.164**0.395±0.196*0.501±0.2260.379±0.136** | 0.433±0.1440.315±0.2190.143±0.103**0.315±0.1300.333±0.2080.399±0.212 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200710095997A CN100593413C (zh) | 2007-04-04 | 2007-04-04 | 一种用于治疗妇科炎症的药物组合物及其制备方法和有效成分检测方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200710095997A CN100593413C (zh) | 2007-04-04 | 2007-04-04 | 一种用于治疗妇科炎症的药物组合物及其制备方法和有效成分检测方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101028384A true CN101028384A (zh) | 2007-09-05 |
CN100593413C CN100593413C (zh) | 2010-03-10 |
Family
ID=38714036
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200710095997A Active CN100593413C (zh) | 2007-04-04 | 2007-04-04 | 一种用于治疗妇科炎症的药物组合物及其制备方法和有效成分检测方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100593413C (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102727594A (zh) * | 2012-06-17 | 2012-10-17 | 宋青春 | 一种治疗肾阳虚型滴虫性阴道炎的中药洗剂制备方法 |
CN102846858A (zh) * | 2012-04-10 | 2013-01-02 | 江西青春康源制药有限公司 | 一种抑菌型药物组合物 |
CN103211920A (zh) * | 2012-01-21 | 2013-07-24 | 上海医药工业研究院 | 广东紫珠低极性成分提取物、含有其的药物组合物、其制备方法及用途 |
CN107334727A (zh) * | 2017-08-08 | 2017-11-10 | 佛山科学技术学院 | 用于尿道或肛门的丁香酚/丁香油栓剂及其制备方法 |
CN108310130A (zh) * | 2018-03-16 | 2018-07-24 | 广州欧盛化妆品有限公司 | 一种治疗外阴炎症的洗剂及其使用方法 |
CN110208420A (zh) * | 2019-06-26 | 2019-09-06 | 贵州中医药大学 | 一种复方黄苦膏的质量检测方法 |
CN110251578A (zh) * | 2019-07-04 | 2019-09-20 | 江西樟树市正康医药生物科技有限公司 | 一种用于缩阴及妇科炎症的药物及其制备方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103215133B (zh) * | 2012-01-21 | 2015-10-21 | 上海医药工业研究院 | 广东紫珠挥发油提取物、其制备方法、含有其的药物组合物及用途 |
-
2007
- 2007-04-04 CN CN200710095997A patent/CN100593413C/zh active Active
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103211920A (zh) * | 2012-01-21 | 2013-07-24 | 上海医药工业研究院 | 广东紫珠低极性成分提取物、含有其的药物组合物、其制备方法及用途 |
CN102846858A (zh) * | 2012-04-10 | 2013-01-02 | 江西青春康源制药有限公司 | 一种抑菌型药物组合物 |
CN102727594A (zh) * | 2012-06-17 | 2012-10-17 | 宋青春 | 一种治疗肾阳虚型滴虫性阴道炎的中药洗剂制备方法 |
CN102727594B (zh) * | 2012-06-17 | 2013-12-04 | 宋青春 | 一种治疗肾阳虚型滴虫性阴道炎的中药洗剂制备方法 |
CN107334727A (zh) * | 2017-08-08 | 2017-11-10 | 佛山科学技术学院 | 用于尿道或肛门的丁香酚/丁香油栓剂及其制备方法 |
WO2019028938A1 (zh) * | 2017-08-08 | 2019-02-14 | 佛山科学技术学院 | 用于尿道或肛门的丁香酚/丁香油栓剂及其制备方法 |
CN108310130A (zh) * | 2018-03-16 | 2018-07-24 | 广州欧盛化妆品有限公司 | 一种治疗外阴炎症的洗剂及其使用方法 |
CN110208420A (zh) * | 2019-06-26 | 2019-09-06 | 贵州中医药大学 | 一种复方黄苦膏的质量检测方法 |
CN110251578A (zh) * | 2019-07-04 | 2019-09-20 | 江西樟树市正康医药生物科技有限公司 | 一种用于缩阴及妇科炎症的药物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN100593413C (zh) | 2010-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101028384A (zh) | 一种用于治疗妇科炎症的药物组合物及其制备方法和质量控制方法 | |
CN1768812A (zh) | 一种用于除湿止痒的药物组合物及其制备方法和用途 | |
CN1698815A (zh) | 一种中药膏剂组合物、其制备方法、其巴布剂及其制备方法 | |
CN1908144A (zh) | 一种肥皂及其制备方法 | |
CN111920882B (zh) | 一种用于夏季呼吸道疾病的药物组合物 | |
CN1444977A (zh) | 含如意金黄散有效部位的药物组合物及其制备方法 | |
CN1513447A (zh) | 竹叶总黄酮在前列腺疾病防治药物及其保健食品中的应用 | |
CN1772136A (zh) | 一种用于治疗筋腱软组织损伤及骨关节病的药物组合物及制备方法 | |
CN1608648A (zh) | 一种具有抗菌作用的中药组合物及制备方法 | |
CN1056298C (zh) | 一种治疗软组织损伤的外用药及其生产方法 | |
CN101028325A (zh) | 一种含有塞隆骨的药物组合物及其制备方法和质量控制方法 | |
CN1850202A (zh) | 一种阴道外用药物组合物及其制备方法和用途 | |
CN114522197B (zh) | 天然抑菌组合物及其应用 | |
CN101062085A (zh) | 一种治疗尖锐湿疣的药物 | |
CN1304038C (zh) | 一种治疗阴道炎的药物组合物及其制备和质量控制方法 | |
CN1751713A (zh) | 菘黄感冒颗粒的配方及其制备方法 | |
CN1895521A (zh) | 一种治疗妇科和皮肤科疾病的中药复方制剂及其制备方法 | |
CN112294929A (zh) | 一种妇科中药盐洗液及其制备方法和应用 | |
CN1927161A (zh) | 一种沐浴乳及其制备方法 | |
CN1895592A (zh) | 一种治疗面部痤疮的中药复方制剂及其制备方法 | |
CN1308019C (zh) | 一种治疗急慢性盆腔炎的中药组合物及制备方法 | |
CN113876851B (zh) | 一种香柏洗液及其制备方法以及在动物真菌性皮肤病中的应用 | |
CN1220515C (zh) | 一种治疗咽喉疾病的药物 | |
CN103495090B (zh) | 治疗阴道炎的中药组合物及其制备方法 | |
CN1186073C (zh) | 一种治疗生殖器疱疹的药物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder |
Address after: 330115 Jiangxi city of Nanchang province Beijiao Xin Qi Zhou Songhai Road No. 490 Patentee after: Jiangxi Xinglin Baima Pharmaceutical Co.,Ltd. Address before: 330115 Jiangxi city of Nanchang province Beijiao Xin Qi Zhou Songhai Road No. 490 Patentee before: JIANGXI XINGLIN BAIMA PHARMACEUTICAL Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Medicinal composition for treating gynaecologic phlogosis, its production and quality controlling method Effective date of registration: 20200415 Granted publication date: 20100310 Pledgee: Nanchang Honggutan sub branch of Bank of China Ltd. Pledgor: Jiangxi Xinglin Baima Pharmaceutical Co.,Ltd. Registration number: Y2020980001517 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210512 Granted publication date: 20100310 Pledgee: Nanchang Honggutan sub branch of Bank of China Ltd. Pledgor: Jiangxi Xinglin Baima Pharmaceutical Co.,Ltd. Registration number: Y2020980001517 |
|
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: No. 231 Guoyao North Avenue, Xinqizhou Management Office, Ganjiang New District, Jiangxi Province, 330000 Patentee after: Jiangxi Xinglin Baima Pharmaceutical Co.,Ltd. Address before: 330115 Jiangxi city of Nanchang province Beijiao Xin Qi Zhou Songhai Road No. 490 Patentee before: Jiangxi Xinglin Baima Pharmaceutical Co.,Ltd. |